RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product

Contributed by: Business Wire

Logo

Business Wire logo

Images

RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.
RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege.
Business Wire embedded0

Tags

Research
Medical Devices
Surgery
FDA
Dental
Clinical Trials
Biotechnology
Alternative Medicine
Health
Science
RevBio, Inc.

More Like This

Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization

Inside information: Bioretec's European market authorization for RemeOs trauma screw has proceeded to expert panel evaluation, the approval is estimated during the Q2 2024

Inside information: Bioretec estimates that the approval of the European market authorization for the biodegradable RemeOs™ trauma screw will move to the first quarter of 2024

Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Inside information: Bioretec Ltd. receives CE mark approval for RemeOs™ Trauma Screw product portfolio, allowing market launch in Europe

Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures

The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

PR Newswire associated0

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study